Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
Perspectives on the results of recent clinical outcomes trials with EPA prevention
P. Gabriel Steg, MD
Challenges in ASCVD reduction and TG-related risk
Erik Stroes MD, PhD
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.